The India-UK free trade agreement (FTA) will not require patent term extensions or data exclusivity, protecting India's ...

In an exclusive interview with Business Today, D. Sridhar Babu, Minister for Information Technology, Industries and Commerce, ...

India-UK FTA excludes patent term extensions and data exclusivity, safeguarding Indian generic drug industry interests.

Indian pharmaceutical market saw a late surge in June, with growth during the quarter primarily driven by cardiac, ...

The deal eliminates tariff barriers and aims to ease regulatory processes, creating room for Indian companies to expand in ...

Export of Indian medical devices to the UK went up by 13 per cent in FY24 as compared to the previous year. These devices ...

India has the potential to turn that principle into practice by making the next generation of therapies not only practical but also accessible and affordable. If it succeeds, India won’t just lead the ...

Shift is expected to drive a sharp increase in generic drug launches, positioning Indian drugmakers for strong growth ...

The PRIP scheme has been launched with an outlay of Rs 5,000 crore to transform India’s Pharma MedTech sector from cost- to ...

The deal, which eliminates tariffs on most finished pharmaceutical products and medical devices, is expected to boost India’s exports to the UK valued at over $914 million grew 18% year-on-year (YoY) ...

The India-UK trade agreement heralds significant developments in the pharmaceutical sector, fostering collaboration in drug imports and research. The deal boosts economic ties, strengthens supply ...

YANGON: The Embassy of India in Myanmar, in collaboration with the India-Myanmar Chamber of Commerce and Industry (IMCCI), hosted the "PHARMA CONNECT 2025" event on the evening of July 25 at the Pan ...